Orforglipron 在 2 型糖尿病中的心血管安全性和治疗潜力：来自 ACHIEVE-4 3 期试验的发现
Posted inClinical Updates Diabetes & Endocrinology news

Cardiovascular Safety and Therapeutic Potential of Orforglipron Versus Insulin Glargine in Type 2 Diabetes with Elevated Cardiovascular Risk: Insights from the ACHIEVE-4 Phase 3 Trial

A comprehensive review of the ACHIEVE-4 trial confirms orforglipron's cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety profile advantages.
Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy
Posted inDiabetes & Endocrinology news

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders compared with propensity‑matched unexposed pregnancies.
Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)
Posted inDiabetes & Endocrinology news

Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)

Maternally inherited diabetes and deafness (MIDD) is driven by m.3243A>G mitochondrial mutation with mixed β‑cell failure and insulin resistance. GLP‑1 receptor agonists and SGLT2 inhibitors have biologic plausibility and cardiorenal benefits in MIDD; we propose a pathophysiology‑driven treatment algorithm and practical monitoring guidance.
Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Posted inClinical Updates Diabetes & Endocrinology Specialties

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.